8-K: Helius Medical Technologies Faces Nasdaq Delisting Threat Due to Low Share Price

Helius Medical Technologies has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing it at risk of delisting.

Summary

• Helius Medical Technologies received a notification from Nasdaq on August 9, 2024, stating that its Class A common stock has traded below $1.00 for 30 consecutive business days.
• This non-compliance with Nasdaq's minimum bid price requirement puts the company at risk of being delisted from the Nasdaq Capital Market.
• Helius has 180 calendar days, until February 5, 2025, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days.
• If the company fails to meet this requirement by February 5, 2025, it may be eligible for an additional 180 days if it meets other listing requirements, excluding the bid price.
• If the company does not regain compliance within the allotted time, Nasdaq will issue a delisting notice, which the company can appeal.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the delisting notice, creating uncertainty about the company's future. The sentiment is negative due to the risk of delisting and the company's failure to maintain the minimum share price.

Positives

• Helius has been granted a 180-day period to regain compliance with the minimum bid price requirement.
• The company may be eligible for an additional 180-day extension if it meets other listing requirements.

Negatives

• The company's stock price has fallen below the minimum bid price requirement of $1.00 for 30 consecutive business days.
• Helius faces the risk of being delisted from the Nasdaq Capital Market if it does not regain compliance.

Risks

• There is no guarantee that Helius will be able to regain compliance with the minimum bid price requirement within the given timeframe.
• The company may not be eligible for an extension, increasing the risk of delisting.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Future Outlook

The company intends to actively monitor its stock price and consider options to regain compliance with Nasdaq listing requirements, but there is no assurance of success.

Management Comments

• The company intends to continue actively monitoring the closing bid price for the Companys Class A common stock between now and February 5, 2025, and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Industry Context

This delisting notice highlights the challenges faced by smaller companies in maintaining stock prices above minimum thresholds, particularly in volatile market conditions.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially those with volatile stock prices.
• Companies like Helius often rely on positive clinical trial results or regulatory approvals to boost their stock price, and failure to achieve these milestones can lead to non-compliance issues.
• Other companies that have faced similar delisting notices include [insert comparable companies if known], which often implement strategies such as reverse stock splits or capital raises to regain compliance.

Stakeholder Impact

• Shareholders face the risk of losing value if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• The company will actively monitor its stock price.
• The company will consider options to regain compliance with Nasdaq listing requirements.
• The company may seek an extension to the compliance period.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, Helius Medical Technologies, stock price, HSDT